Ofne - Ofne is a fluoroquinolone antibiotic considered to be a second-generation fluoroquinolone. Floxin (branded version) had been discontinued by the manufacturer, in the United States, effective June 18, 2009, though generic equivalents continue to be available.
Ofne is a racemic mixture, which consists of 50% levofloxacin (the biologically active component) and 50% of its “mirror image” or enantiomer dextrofloxacin. When levofloxacin disks were not available in early clinical trials, a 5-pg Floxin (ofloxacin –floxacin) disk was substituted. The U.S. Food and Drug Administration (FDA) medical reviewers considered the two drugs to be one and the same and hence interchangeable.
Like other quinolones, Ofne has been associated with a significant number of serious adverse drug reactions, such as tendon damage (including spontaneous tendon ruptures) and peripheral neuropathy (which may be irreversible); such reactions may manifest long after therapy had been completed, and, in severe cases, may result in life-long disabilities. Ofloxacin has also been associated with severe psychiatric adverse reactions.
Hepatotoxicity has also been reported with the use of ofloxacin. Case reports of hepatitis have been published for the older fluoroquinolones including ciprofloxacin, ofloxacin, and norfloxacin.
Indications: Genito urinary, respiratory, gastro intestinal.
skin and soft tissue infections.
Typhoid fever, Multi drug resistant tuberculosis.
Acute and sub-acute eye and ear infections.